製品の概要

  • 製品名Anti-Warfarin antibody
  • 製品の詳細
    Sheep polyclonal to Warfarin
  • アプリケーション適用あり: ELISA, Competitive ELISA, Purificationmore details
  • 免疫原

    Warfarin conjugated to Bovine thyroglobulin.

製品の特性

  • 製品の状態Liquid
  • 保存方法Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
  • バッファーPreservative: 0.09% Sodium azide
    Constituents: 0.33% Sodium phosphate, 0.88% Sodium chloride
  • Concentration information loading...
  • 精製度IgG fraction
  • ポリ/モノポリクローナル
  • アイソタイプIgG
  • 研究分野

アプリケーション

Our Abpromise guarantee covers the use of ab123975 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
ELISA Use a concentration of 2.5 µg/ml.
Competitive ELISA Use a concentration of 2.5 µg/ml. 10ng/ml Warfarin produces 69% inhibition in a competitive ELISA employing ab123975
Purification Use a concentration of 2.5 µg/ml. ab123975 is suitable for the development of immunoaffinity purification columns.

ターゲット情報

  • 関連性Warfarin, a synthetic derivative of coumarinan, is an anticoagulant medication used for the prophylaxis of thrombosis and embolism in many disorders. It was originally developed as a rat poison, and is still widely used as such, although warfarin-resistant rats are becoming more common. Warfarin inhibits the effective synthesis of biologically active forms of the vitamin K-dependent clotting factors: II, VII, IX and X, as well as the regulatory factors protein C, protein S and protein Z. Other proteins not involved in blood clotting, such as osteocalcin, may also be affected. The precursors of these factors require carboxylation of their glutamic acid residues to allow the coagulation factors to bind to phospholipid surfaces. This carboxylation is linked to oxidation of vitamin K to form Vitamin K epoxide, which is in turn recycled back to the reduced form by the enzyme epoxide reductase. Warfarin inhibits epoxide reductase, thereby diminishing vitamin K action and inhibiting production of functioning coagulation factors. As the body's stores of previously-produced factors degrade (over several days), the anticoagulation effect becomes apparent. The coagulation factors are produced, but have decreased functionality due to undercarboxylation; they are collectively referred to as PIVKAs (proteins induced [by] vitamin K absence/antagonism).

Anti-Warfarin antibody (ab123975) 使用論文

ab123975 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab123975.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"